XML 43 R33.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Collaboration agreements - Merck KGaA (Details) | 1 Months Ended | 3 Months Ended | 9 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | ---
Jun. 30, 2014 USD ($) target | Sep. 30, 2022 USD ($) target | Sep. 30, 2021 USD ($) | Sep. 30, 2022 USD ($) target | Sep. 30, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2017 target
Collaboration agreements |  |  |  |  |  |  |  |
Research and development |  | $ 50,639,000 | $ 35,275,000 | $ 127,676,000 | $ 94,645,000 |  |  |
Merck KGaA |  |  |  |  |  |  |  |
Collaboration agreements |  |  |  |  |  |  |  |
Proceeds from collaborators | $ 12,000,000 |  |  |  |  |  |  |
Number of targets designated | target | 6 | 6 |  | 6 |  |  |  | 6
Amount of additional fees receivable when target is designated and commercial license to target is granted | $ 0 |  |  |  |  |  |  |
Next potential development milestone payment eligible to receive |  | $ 500,000 |  | $ 500,000 |  |  |  |
Number of targets with satisfied performance obligations | target |  |  |  | 4 |  |  |  |
Merck KGaA | Rights to Future Technological Improvements | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 |  |  |  |  |  |  |  |
Collaboration agreements |  |  |  |  |  |  |  |
Expected recognition period |  | 10 years |  | 10 years |  |  |  |
Merck KGaA | Joint Research Committee Services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 |  |  |  |  |  |  |  |
Collaboration agreements |  |  |  |  |  |  |  |
Expected recognition period |  | 5 years |  | 5 years |  |  |  |
License and supply agreement Merck KGaA |  |  |  |  |  |  |  |
Collaboration agreements |  |  |  |  |  |  |  |
Deferred revenue |  | $ 3,912,000 | 3,955,000 | $ 3,912,000 | 3,955,000 | $ 3,944,000 | $ 3,987,000 |
Merck KGaA Supply Agreement |  |  |  |  |  |  |  |
Collaboration agreements |  |  |  |  |  |  |  |
Research and development |  | $ 0 | $ 0 | $ 0 | $ 0 |  |  |

X
- Definition Amount of additional fees receivable when a target is designated and the commercial license to the target is granted under terms of the agreement. + References No definition available. + Details
Name: | mrsn_CollaborationArrangementsAdditionalPaymentToObtainDevelopmentAndCommercialLicense
Namespace Prefix: | mrsn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of the next potential development milestone the company will be eligible to receive. + References No definition available. + Details
Name: | mrsn_CollaborationArrangementsDevelopmentMilestonesPaymentReceivableNextMilestone
Namespace Prefix: | mrsn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of targets designated as of balance sheet date. + References No definition available. + Details
Name: | mrsn_CollaborationArrangementsTargetsDesignatedNumber
Namespace Prefix: | mrsn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of designated targets for which performance obligations have been satisfied during the period. + References No definition available. + Details
Name: | mrsn_CollaborationArrangementsTargetsDesignatedPerformanceObligationsSatisfiedNumber
Namespace Prefix: | mrsn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementMerckKgaaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrsn_RightsToFutureTechnologicalImprovementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrsn_JointResearchCommitteeServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mrsn_CollaborationAndCommercialLicenseAgreementAndSupplyAgreementMerckKgaaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mrsn_SupplyAgreementMerckKgaaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |